Skip to main content

Advertisement

SpringerLink
Log in

Is There a Role for Stem Cell Therapy for Overactive Bladder?

  • Overactive Bladder (J Sandhu, Section Editor)
  • Published:
Current Bladder Dysfunction Reports Aims and scope Submit manuscript

Abstract

The traditional approach to the treatment of overactive bladder (OAB) consists of behavioral therapies and pharmacologic interventions, both of which are effective in the short term but have failed to demonstrate durability over time. Patients who fail these interventions for OAB have other more invasive surgical options available that carry their own attendant risks. Herein we provide an up-to-date overview of contemporary research being performed in the treatment of OAB. Namely, we discuss the risks and benefits of pharmacogenomic medicine, whereby we can study the genetic differences in metabolic pathways that affect an individual’s response to certain drugs. We also look at molecular medicine and the use of viral vectors to deliver gene therapy to target cells. Finally, we provide an overview of stem cells and the purported therapeutic benefits as well as the challenges faced by researchers in the use of these emerging treatment modalities.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance

  1. Abrams P, Cardozo L, Fall M, et al. The standardisation of terminology in lower urinary tract function: report from the standardisation sub-committee of the International Continence Society. Urology. 2003;61:37–49.

    Article  PubMed  Google Scholar 

  2. Milsom I, Abrams P, Cardozo L, et al. How widespread are the symptoms of an overactive bladder and how are they managed? a population-based prevalence study. BJU Int. 2001;87:760–6.

    Article  PubMed  CAS  Google Scholar 

  3. Stewart WF, Van Rooyen JB, Cundiff GW, et al. Prevalence and burden of overactive bladder in the United States. World J Urol. 2003;20(6):327–36.

    PubMed  CAS  Google Scholar 

  4. Coyne KS, Sexton CC, Kopp ZS, et al. The impact of overactive bladder on mental health, work productivity and health-related quality of life in the UK and Sweden: results from EpiLUTS. BJU Int. March 2011, In press.

  5. Epstein LB, Goldstein RP. The overactive bladder and quality of life. Int J Fertil Women Med. 2005;50:30–6.

    Google Scholar 

  6. Hu-T W. TH: health-related consequences of overactive bladder: an economic perspective. BJU Int. 2005;96 Suppl 1:43–5.

    Article  PubMed  Google Scholar 

  7. Milne JL. Behavioral therapies for overactive bladder: making sense of the evidence. J Wound Ostomy Continence Nurs. 2008;35(1):93–101.

    Article  PubMed  Google Scholar 

  8. Tran K, Levin RM, Mousa SA. Behavioral intervention versus pharmacotherapy or their combinations in the management of overactive bladder dysfunction. Adv Urol. 2009;345324.

  9. Benner JS, Nichol MB, Rovner ES, et al. Patient-reported reasons for discontinuing overactive bladder medication. BJU Int. 2010;105(9):1276–82.

    Article  PubMed  Google Scholar 

  10. • Dmochowski RR, Gomelsky A. Update on the treatment of overactive bladder. Curr Opin Urol. 2011;21(4):286–90. This comprehensive review article summarizes the current therapies directed at the treatment of OAB.

    Article  PubMed  Google Scholar 

  11. Hudson KL. Genomics, healthcare and society. N Engl J Med. 2011;365(11):1033–41.

    Article  PubMed  CAS  Google Scholar 

  12. Chancellor MB. New frontiers in the treatment of overactive bladder and incontinence. Rev Urol. 2002;4 Suppl 4:S50–6.

    PubMed  Google Scholar 

  13. Hristov KL, Chen M, Kellett WF, Rovner ES, Petkov GV. Large-conductance voltage- and Ca2+−activated K+channels regulate human detrusor smooth muscle function. Am J Physiol Cell Physiol. 2011;301(4):C903–12.

    Article  PubMed  CAS  Google Scholar 

  14. Christ GJ, Day NS, Day M, et al. Bladder injection of “naked” hSlo/pcDNA3 ameliorates detrusor hyperactivity in obstructed rats in vivo. Am J Physiol Regul Integr Comp Physiol. 2001;281:R1699–709.

    PubMed  CAS  Google Scholar 

  15. Goins WF, Yoshimura N, Phelan MW, et al. Gene therapy using herpes simplex virus mediated nerve growth factor expression in bladder and afferent neurons: potential treatment for diabetic bladder dysfunction. J Urol. 2001;165:1748–54.

    Article  PubMed  CAS  Google Scholar 

  16. Yoshimura N, Franks ME, Sasaki K, et al. Gene therapy of bladder pain with herpes simplex virus (HSV) vectors expressing preproenkephalin (PPE). Urology. 2001;57(6 Suppl 1):116.

    Google Scholar 

  17. • Yamamoto H, Shah S, Masters JR, Popert RJ, Dasgupta P. Stem cells in regenerative urology of the bladder. BJU Int. 2009;104(9):1183–4. This is a concise review on SCs and regenerative medicine and their applications to urologic diseases of the urinary bladder.

    Article  PubMed  Google Scholar 

  18. Yokoyama T, Yoshimura N, Dhir R, et al. Persistence and survival of autologous muscle derived cells versus bovine collagen as potential treatment of stress urinary incontinence. J Urol. 2001;165:271–6.

    Article  PubMed  CAS  Google Scholar 

  19. •• Lin CS. Advances in stem cell therapy for the lower urinary tract. World J Stem Cells. 2010;2(1):1–4. This is an excellent and comprehensive review of current research in SC therapy as it applies to diseases of the urinary bladder.

    Article  PubMed  Google Scholar 

  20. Usas A, Huard J. Muscle-derived stem cells for tissue engineering and regenerative therapy. Biomaterials. 2007;28:5401–6.

    Article  PubMed  CAS  Google Scholar 

  21. Lin CS, Xin ZC, Deng CH, et al. Defining adipose-tissue-derived stem cells in tissue and in culture. Histol Histopathol. 2010;25(6):807–15.

    PubMed  Google Scholar 

  22. Nishijima S, Sugaya K, Miyazato M, et al. Restoration of bladder contraction by bone marrow transplantation in rats with underactive bladder. Biomed Res. 2007;28:275–80.

    Article  PubMed  CAS  Google Scholar 

  23. Woo LL, Tanaka ST, Anumanthan G, et al. Mesenchymal stem cell recruitment and improved bladder function following bladder outlet obstruction: preliminary data. J Urol. 2011;185(3):1132–8.

    Article  PubMed  Google Scholar 

  24. Huang YC, Shindel AW, Ning H, et al. Adipose derived stem cells ameliorate hyperlipidemia associated detrusor over activity in a rat model. J Urol. 2010;183:1232–40.

    Article  PubMed  CAS  Google Scholar 

  25. Lin CS. Stem cell therapy for the bladder—where do we stand? J Urol. 2011;185(3):779–80.

    Article  PubMed  Google Scholar 

  26. De Coppi P, Callegari A, Chiavegato A, et al. Amniotic fluid and bone marrow derived mesenchymal stem cells can be converted to smooth muscle cells in the cryoinjured rat bladder and prevent compensatory hypertrophy of surviving smooth muscle cells. J Urol. 2007;177:369–76.

    Article  PubMed  Google Scholar 

  27. Vricella GJ, Tao M, Altuntas CZ, et al. Expression of monocyte chemotactic protein 3 following simulated birth trauma in a murine model of obesity. Urology. 2010;76(6):1517.e12–7.

    Article  Google Scholar 

  28. Caplan AI. Adult mesenchymal stem cells for tissue engineering versus regenerative medicine. J Cell Physiol. 2007;213(2):341–7.

    Article  PubMed  CAS  Google Scholar 

  29. Caplan AI, Dennis JE. Mesenchymal stem cells as trophic mediators. J Cell Biochem. 2006;98(5):1076–84.

    Article  PubMed  CAS  Google Scholar 

  30. Condic ML, Rao M. Regulatory issues for personalized pluripotent cells. Stem Cells. 2008;26(11):2753–8.

    Article  PubMed  CAS  Google Scholar 

  31. Bongso A, Fong CY, Gauthaman K. Taking stem cells to the clinic: major challenges. J Cell Biochem. 2008;105(6):1352–60.

    Article  PubMed  CAS  Google Scholar 

  32. Schuldiner M, Eiges R, Eden A, et al. Induced neuronal differentiation of human embryonic stem cells. Brain Res. 2001;913:201–5.

    Article  PubMed  CAS  Google Scholar 

  33. Fujikawa T, Oh SH, Pi L, et al. Teratoma formation leads to failure of treatment for type 1 diabetes using embryonic stem cell-derived insulin-producing cells. Am J Pathol. 2005;166:1781–91.

    Article  PubMed  CAS  Google Scholar 

  34. Cao F, Lin S, Xiaoyan X, et al. In vivo visualization of embryonic stem cell survival, proliferation and migration after cardiac delivery. Circulation. 2006;113:1005–14.

    Article  PubMed  Google Scholar 

Download references

Disclosure

No potential conflicts of interest relevant to this article were reported.

Author information

Authors and Affiliations

  1. Urology Institute, Department of Urology, University Hospitals Case Medical Center, Case Western Reserve University, Lakeside Building, 4th Floor, 11100 Euclid Avenue, Cleveland, OH, 44106, USA

    Gino J. Vricella

  2. Urology Institute, Department of Urology, Division of Female Pelvic Surgery, University Hospitals Case Medical Center, Case Western Reserve University, Lakeside Building, 4th Floor, 11100 Euclid Avenue, Cleveland, OH, 44106, USA

    Adonis K. Hijaz

Authors
  1. Gino J. Vricella
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Adonis K. Hijaz
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Adonis K. Hijaz.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Vricella, G.J., Hijaz, A.K. Is There a Role for Stem Cell Therapy for Overactive Bladder?. Curr Bladder Dysfunct Rep 7, 14–18 (2012). https://doi.org/10.1007/s11884-011-0115-6

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11884-011-0115-6

Keywords

Search

Navigation